Skip to main
SWTX
SWTX logo

SWTX Stock Forecast & Price Target

SWTX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 33%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

SpringWorks Therapeutics Inc. is strategically positioned to capitalize on its recent product approvals, OGSIVEO and GOMEKLI, which are expected to drive significant market interest and create potential acquisition opportunities within the biopharmaceutical sector. With approximately $461.9 million in cash and cash equivalents as of the end of 2024, the company is well-funded to support its operations until projected profitability in 2026. The competitive clinical profiles of its products, particularly GOMEKLI's broader market access compared to existing treatments, enhance its outlook for outperforming initial estimates, underscoring SpringWorks's attractiveness as a promising oncology enterprise.

Bears say

SpringWorks Therapeutics is projected to incur a full-year net loss of $2.65 million in 2025, indicating potential financial strain. The company faces substantial risks related to the commercialization and market expansion of its key products, nirogacestat and mirdametinib, as well as the possibility of clinical setbacks with other candidates like brimarafenib. Additionally, the threat of long-term dilution poses a further risk to investors, particularly in light of the dependence on achieving regulatory and clinical success for its developmental programs.

SWTX has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 33% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SpringWorks Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SpringWorks Therapeutics Inc (SWTX) Forecast

Analysts have given SWTX a Buy based on their latest research and market trends.

According to 9 analysts, SWTX has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SpringWorks Therapeutics Inc (SWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.